Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

OTC Markets OTCPK - Delayed Quote USD

Mosaic ImmunoEngineering, Inc. (CPMV)

0.9800

+0.3180

+(48.04%)

At close: February 21 at 3:00:00 PM EST

Oncotelic Therapeutics, Inc. to Sell Its Necroptosis Cancer Therapy Assets to Mosaic ImmunoEngineering, Inc.

AGOURA HILLS, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), announced today that it has entered into a binding term-sheet with Mosaic ImmunoEngineering, Inc. (OTCPK: CPMV) (“Mosaic”) under which Mosaic will acquire rights to Oncotelic’s clinical-stage necroptosis cancer therapies. Oncotelic’s necroptosis therapeutics work by disrupting tumor blood flow resulting in immunogenic tumor cell death through “death re

GlobeNewswire 9 months ago

OTLC
-13.04%
CPMV
+48.04%
Mosaic ImmunoEngineering Agrees to Acquire Clinical Necroptosis Cancer Therapy Assets from Oncotelic Therapeutics, Inc.

- The clinical assets to be acquired include cancer and ocular disease programs, including regulatory and clinical packages and access to Oncotelic's AI platform for identifying immunotherapy combinations HUNTINGTON BEACH, CA / ACCESSWIRE / April ...

ACCESS Newswire 9 months ago

CPMV
+48.04%

Performance Overview

Return	CPMV	S&P 500
YTD	+39.80%	+2.24%
1-Year	+66.10%	+20.70%
3-Year	0.00%	+38.27%